Calendrier des promotions Biogen
Calendrier avancé
Graphique simple
À propos de l'entreprise Biogen
Biogen Inc. — американская многонациональная биотехнологическая компания, базирующаяся в Кембридже, штат Массачусетс, специализирующаяся на открытии, разработке и поставке методов лечения нейродегенеративных, гематологических и аутоиммунных заболеваний пациентам во всем мире.Paramètres de base
IPO date
1991-09-16
ISIN
US09062X1037
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Дивиденд ао
22.23
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 2.26 | 6 |
| P/BV | 1.31 | 9 |
| P/E | 13.43 | 8 |
Efficacité
| Nom | Signification | Grade |
| ROA | 5.95 | 2 |
| ROE | 10.36 | 4 |
| ROIC | 8.77 | 3 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0.5 | 5 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 2.55 | 5 |
| Debt/Ratio | 0.2364 | 10 |
| Debt/Equity | 0.678 | 9 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | -28.01 | 0 |
| Rentabilité Ebitda, % | -68.39 | 0 |
| Rentabilité EPS, % | -54.89 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 125.81 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 129.44 $ | 0 $ | 0 $ | -2.8 % | 0 % | 0 % |
| common.calendar.number_days.30d | 119.51 $ | 120.37 $ | 130.55 $ | 5.27 % | 0 % | 0 % |
| common.calendar.number_days.90d | 141.27 $ | 113.38 $ | 143.66 $ | -10.94 % | 0 % | 0 % |
| common.calendar.number_days.180d | 157.69 $ | 113.38 $ | 157.46 $ | -20.22 % | 0 % | 0 % |
| common.calendar.number_days.1y | 217.81 $ | 113.38 $ | 236.8 $ | -42.24 % | 0 % | 0 % |
| common.calendar.number_days.3y | 192.4 $ | 113.38 $ | 324.5 $ | -34.61 % | 0 % | 0 % |
| common.calendar.number_days.5y | 265.72 $ | 113.38 $ | 422.32 $ | -52.65 % | 0 % | 0 % |
| common.calendar.number_days.10y | 238.31 $ | 113.38 $ | 422.32 $ | -47.21 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 146.79 $ | 113.38 $ | 153.27 $ | -14.29 % | 0 % | 0 % |
Délit d'initié
Principaux propriétaires
Contenu dans l'ETF
| ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| PSYK ETF | 4.07 | 0 | 0.75 |
| Future Tech ETF | 2.81727 | 426.34 | 0.35 |
| Principal Healthcare Innovators ETF | 2.81727 | 618.5 | 0.35 |
| IQ U.S. Mid Cap R&D Leaders ETF | 2.48 | 0 | 0.16 |
| John Hancock Multifactor Healthcare ETF | 2.34 | 29.34 | 0.40 |
| iShares Evolved U.S. Innovative Healthcare ETF | 2.29 | 0.000586 | 0.18 |
| Invesco S&P 500® Equal Weight Health Care ETF | 1.77 | 815.08 | 0.40 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.52 | 26.65 | 0.34 |
| IQ Engender Equality ETF | 1.05205 | 30.64 | 0.45 |
| Knowledge Leaders Developed World ETF | 0.91244 | 14.17 | 0.75 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.32 | 6.26 | 0.09 |
| iShares Morningstar Mid-Cap ETF | 0.26833 | 252.64 | 0.04 |
| Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.19851 | 21.38 | 0.68 |
| JPMorgan U.S. Aggregate Bond ETF | 0.18 | 4.67 | 0.07 |
| iShares Morningstar Large-Cap Value ETF | 0.11151 | 63.9 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.10133 | -99.18 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.05802 | 257.57 | 0.03 |
| 1,37 | 145,17 | 0,33 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | N/A | 1966 (59 années) |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | N/A | |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.46M | 1973 (52 année) |
| Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.12M | 1964 (61 année) |
| Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 2.2M | 1957 (68 années) |
| Mr. Christopher A. Viehbacher | President, CEO & Director | 487.94k | 1961 (64 année) |
| Mr. Charles E. Triano | Senior VP & Head of Investor Relations | N/A | |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | N/A | 1977 (48 années) |
| Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1975 (50 années) | |
| Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1968 (57 années) |
Informations sur l'entreprise
Adresse: United States, Cambridge, 225 Binney Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: http://www.biogen.com
Site web: http://www.biogen.com
